Nonpseudophakic Cystoid Macular Edema

No Results

No Results

processing….

Although the most common cause of cystoid macular edema (CME) is due to Irvine-Gass syndrome of CME after cataract extraction or other intraocular surgery, numerous other conditions are associated with the clinical appearance of fluid-filled, cystoid spaces in the macular region. CME is a final common pathway of many intraocular diseases, usually involving the retinal vasculature. The appearance can differ somewhat, depending on the etiology; however, CME can appear as a nonspecific clinical finding. If the cause of CME is not obvious, detailed ophthalmoscopy and, occasionally, ancillary testing may be necessary to identify the cause.

Cystoid macular edema due to nonproliferative diabetic retinopathy is shown in the image below.

Macular edema is excessive fluid within the layers of the retina, distinct from the accumulation of fluid under or between the retinal layers (eg, subsensory fluid, serous retinal detachment). The amount of fluid normally present in the retina is maintained according to osmotic and hydrostatic pressures between the retina and the surrounding vasculature, which are compartmentalized by the blood-retinal barrier. A breakdown in the blood-retinal barrier allows for fluid to accumulate in cystoid spaces within the retina. Pathologic evidence of cell loss and Müller cell abnormalities may contribute to the resulting CME.

Several mechanisms have been proposed to explain how CME develops. The characteristic distribution of vascular leakage and retinal edema may be explained best by the diffusion of mediators (eg, prostaglandins) released in the eye. These mediators of inflammation cause increased permeability of retinal blood vessels, resulting in extravasion. This theory is supported by evidence that cyclooxygenase inhibitors (eg, indomethacin, other nonsteroidal anti-inflammatory drugs) reduce the incidence of angiographic CME. However, this finding has only been extensively reported on in pseudophakic CME associated with surgical trauma to the anterior segment. A 2013 case report described a phakic patient with idiopathic macular telangiectasia type 1 whose CME reacted robustly to the administration of NSAIDs and would reoccur in the absence of treatment. ^[1]

The major determinant of fluid movement in the retina is the Müller cell. Müller cells have bicarbonate-related transport mechanisms that control movement of potassium and sodium ions (and thus fluid), partly explaining the role for carbonic anhydrase inhibitors such as acetazolamide in the treatment of cystoid macular edema. Additional routes of ion control are achieved through the Kir2.1 and Kir4.1 channels that buffer changes in intracellular potassium.

In addition, evidence shows that the reduced outflow of fluid from the retina is responsible for the buildup of edema. In particular, reduced or absent flow to the deep vascular plexus of the retina has been described. This decreased flow can result from ischemia or inflammation and is mediated by integrins, selectins, and other adhesion molecules. Extravasated leukocytes have the ability to plug capillaries, thus blocking blood flow. ^[2]

Another mechanism emphasizes the role of mechanical factors, such as tractional forces on the macula from disruption of the normal vitreoretinal interface. Even according to this theory, it is believed that local forces induce a release of mediators that lead to a breakdown of the blood-retinal barrier, resulting in the clinical appearance of CME.

Photic injury has been implicated in the development of pseudophakic CME; however, there is no scientific evidence that light damage to the retina causes CME. 

United States

Frequency of CME that is unassociated with cataract surgery varies widely, both in the United States and internationally, depending on the etiology or underlying condition leading to CME. Incidence figures vary because of difficulty in observing subtle CME clinically, surgeon bias in reporting CME, and a lack in performing fluorescein angiography (FA) or optical coherence tomography (OCT) tests that would detect CME.

CME from any etiology often leads to significant central visual loss, typically in the 20/40 to 20/200 range.

No racial predilection has been associated with CME.

CME is distributed equally among males and females.

Age of incidence of nonpseudophakic CME varies according to etiology. Since diabetic CME is secondary to diabetic retinopathy, it occurs in persons aged 40 years and older.

Visual prognosis in eyes with CME depends on the etiology of the CME. If the CME resolves with treatment, visual acuity of 20/40 or better is common. However, in long-standing CME, vision is often 20/100 to 20/200.

Dunn EN, Gregori NZ, Goldhardt R. Phakic cystoid macular edema secondary to idiopathic macular telangiectasia type 1 responsive to topical anti-inflammatory agents. Semin Ophthalmol. 2013 Mar. 28 (2):84-7. [Medline].

Spaide RF. RETINAL VASCULAR CYSTOID MACULAR EDEMA: Review and New Theory. Retina. 2016 Oct. 36 (10):1823-42. [Medline].

Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999 May. 106(5):1024-9. [Medline].

Sivaprasad S, Bunce C, Crosby-Nwaobi R. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev. 2012 Feb 15. 2:CD004239. [Medline].

Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009 May. 20(3):166-74. [Medline].

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct. 121 (10):1904-14. [Medline].

Bressler SB, Glassman AR, Almukhtar T, Bressler NM, Ferris FL, Googe JM Jr, et al. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol. 2016 Apr. 164:57-68. [Medline].

Liu L, Wu X, Geng J, Yuan Z, Chen L. IVTA as Adjunctive Treatment to PRP and MPC for PDR and Macular Edema: A Meta-Analysis. PLoS One. 2012. 7(9):e44683. [Medline]. [Full Text].

Parke DW 3rd, Sisk RA, Murray TG. Intraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification. Clin Ophthalmol. 2012. 6:1347-53. [Medline]. [Full Text].

Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With Ranibizumab. Arch Ophthalmol. 2012 Sep 1. 130(9):1153-1161. [Medline].

Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina. 2008 Oct. 28(9):1325-37. [Medline].

Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev. 2009 Feb. 5(1):39-46. [Medline].

Altintas O, Yuksel N, Karabas VL, Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005 Jan-Feb. 15(1):158-61. [Medline].

Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001 Apr. 108(4):765-72. [Medline].

Boscia F, Furino C, Dammacco R. Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results. Eur J Ophthalmol. 2005 Jan-Feb. 15(1):89-95. [Medline].

Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998 Jul. 126(1):134-5. [Medline].

Conway MD, Canakis C, Livir-Rallatos C. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003 Jan. 29(1):27-33. [Medline].

Falcone PM. Vitreomacular traction syndrome confused with pseudophakic cystoid macular edema. Ophthalmic Surg Lasers. 1996 May. 27(5):392-4. [Medline].

Feldman RB, Mayo SS, Robertson DM, Jones JD, Rostvold JA. Epiretinal membranes and cystoid macular edema in gyrate atrophy of the choroid and retina. Retina. 1989. 9(2):139-42. [Medline].

Fung WE. Retina. Other causes of cystoid macular edema and retinal trauma after surgery. 1994. 2(2): 1811-7.

Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006 Oct. 26(8):889-95. [Medline].

Halperin LS, Goldman HB. Cystoid macular edema associated with topical echothiophate iodide. Ann Ophthalmol. 1993 Dec. 25(12):457-8. [Medline].

Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 1999 May. 127(5):565-73. [Medline].

Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998 May. 116(5):680-2. [Medline].

Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol. 1999 Aug. 128(2):185-91. [Medline].

Igarashi H, Igarashi S, Ishiko S, Fukui K, Yoshida A. Cystoid macular edema as an initial symptom of inflammatory orbital pseudotumor. Ophthalmologica. 1997. 211(4):236-41. [Medline].

Ikeda T, Sato K, Katano T, Hayashi Y. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol. 1999 Apr. 127(4):478-9. [Medline].

Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004 Aug. 122(8):1131-6. [Medline].

Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2005 Jan. 19(1):65-71. [Medline].

Kersten AJ, Althaus C, Best J, Sundmacher R. Cystoid macular edema following immune recovery and treatment with cidofovir for cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. 1999 Nov. 237(11):893-6. [Medline].

Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006 Sep. 142(3):405-12. [Medline].

Lee ST, Friedman SM, Rubin ML. Cystoid macular edema secondary to juxtafoveolar telangiectasis in Coats’ disease. Ophthalmic Surg. 1991 Apr. 22(4):218-21. [Medline].

Loeffler KU, Li ZL, Fishman GA, Tso MO. Dominantly inherited cystoid macular edema. A histopathologic study. Ophthalmology. 1992 Sep. 99(9):1385-92. [Medline].

Maguire AM, Nichols CW, Crooks GW. Visual loss in cytomegalovirus retinitis caused by cystoid macular edema in patients without the acquired immune deficiency syndrome. Ophthalmology. 1996 Apr. 103(4):601-5. [Medline].

McDonnell PJ, Ryan SJ, Walonker AF, Miller-Scholte A. Prediction of visual acuity recovery in cystoid macular edema. Ophthalmic Surg. 1992 May. 23(5):354-8. [Medline].

Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica. 2007. 221(2):118-31. [Medline].

Michael JC, De Venecia G. Retinal trypsin digest study of cystoid macular edema associated with peripheral choroidal melanoma. Am J Ophthalmol. 1995 Feb. 119(2):152-6. [Medline].

Mishima H, Masuda K, Miyake K. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res. 1989. 312:251-64. [Medline].

Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003 Sep. 136(3):419-25. [Medline].

Park DW, Folk JC, Whitcup SM, Polk TD, Kansupada K, Fountain C, et al. Phakic patients with cystoid macular edema, retinal periphlebitis, and vitreous inflammation. Arch Ophthalmol. 1998 Aug. 116(8):1025-9. [Medline].

Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007 Apr-May. 27(4):419-25. [Medline].

Remky A, Beausencourt E, Hartnett ME, Trempe CL, Arend O, Elsner AE. Infrared imaging of cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 1999 Nov. 237(11):897-901. [Medline].

Rocha G, Deschênes J. Pathophysiology and treatment of cystoid macular edema. Can J Ophthalmol. 1996 Oct. 31(6):282-8. [Medline].

Rumelt S, Kraus E, Rehany U. Retinal neovascularization and cystoid macular edema in punctata albescens retinopathy. Am J Ophthalmol. 1992 Oct 15. 114(4):507-8. [Medline].

Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009 Apr. 29(4):511-5. [Medline].

Schubert HD. Cystoid macular edema: the apparent role of mechanical factors. Prog Clin Biol Res. 1989. 312:277-91. [Medline].

Silverstein BE, Smith JH, Sykes SO, Jones MR, Schwartz D, Cunningham ET Jr. Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1998 Mar. 125(3):411-5. [Medline].

Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-Tenon’s corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology. 1997 Dec. 104(12):2003-8. [Medline].

van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006 Apr. 14(2):73-85. [Medline].

Weene LE. Cystoid macular edema after scleral buckling responsive to acetazolamide. Ann Ophthalmol. 1992 Nov. 24(11):423-4. [Medline].

Welzl-Hinterkorner E, Tholen H, Sturmer J, Opravil M, Bernauer W. [Bilateral cystoid macular edema after successful treatment of AIDS-associated cytomegalovirus retinitis]. Ophthalmologe. 1999 Feb. 96(2):87-91. [Medline].

Wen JC, McCannel TA. Treatment of radiation retinopathy following plaque brachytherapy for choroidal melanoma. Curr Opin Ophthalmol. 2009 May. 20(3):200-4. [Medline].

Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology. 1996 Jul. 103(7):1054-62; discussion 1062-3. [Medline].

Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL. Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging. 2005 Jan-Feb. 36(1):30-6. [Medline].

Hamoon Eshraghi, MD Resident Physician, Transitional Year, St Luke’s Hospital

Hamoon Eshraghi, MD is a member of the following medical societies: Medical Society of New Jersey

Disclosure: Nothing to disclose.

Howard F Fine, MD, MHSc Partner, Associated Retina Consultants, Retina Vitreous Center, PA; Co-founder and Chairman of Scientific Advisory Board, Auris Surgical Robotics, Inc

Howard F Fine, MD, MHSc is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, Association for Research in Vision and Ophthalmology, American Society of Retina Specialists

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Steve Charles, MD Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

V Al Pakalnis, MD, PhD Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, South Carolina Medical Association

Disclosure: Nothing to disclose.

Daniel B Roth, MD Assistant Professor, Department of Ophthalmology, Retina Vitreous Center, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

Daniel B Roth, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Society of Retina Specialists, Retina Society, American Medical Association

Disclosure: Nothing to disclose.

Nonpseudophakic Cystoid Macular Edema

Research & References of Nonpseudophakic Cystoid Macular Edema|A&C Accounting And Tax Services
Source

Share on Facebook

Tweet

Follow us